Kardigan, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KARD research report →
Range $25 – $50
Price Chart
About the company
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes.
- CEO
- Tassos Gianakakos
- IPO
- 2026
- Employees
- 241
- HQ
- Princeton, NJ, US
Get TickerSpark's AI analysis on KARD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.30B
- P/E
- -7.09
- PEG
- -0.07
- P/S
- 0.00
- P/B
- 2.31
- EV/EBITDA
- -7.60
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -109.44%
- ROIC
- -20.43%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-201,836,000
- Net Income
- $-191,941,000+0.0%
- EPS
- $-3.20+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $27.00
- 52W Low
- $12.23
- 50D MA
- $15.44
- 200D MA
- $18.66
- Beta
- 6.05
- RSI (14)
- 58
- Avg Volume
- 593.20K
No earnings-call transcripts are available for KARD yet.
- Free Float
- 57.9%
- Shares Outstanding
- 89.34M
- Float Shares
- 51.76M
of shares held by institutions
69 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Hrtg Gpe, LLC | 16.92M | ▲ 16.92M |
| Fmr LLC | 8.91M | ▲ 8.91M |
| Perceptive Advisors LLC | 8.20M | ▲ 8.20M |
| T. Rowe Price Investment Management, Inc. | 4.21M | ▲ 4.21M |
| Capital Research Global Investors | 3.60M | ▲ 3.60M |
| Jpmorgan Chase & Co | 1.79M | ▲ 1.79M |
| Alliancebernstein L.P. | 1.53M | ▲ 1.53M |
| Liberty Mutual Group Asset Management Inc. | 1.20M | ▲ 1.20M |
| Jennison Associates LLC | 903.58K | ▲ 903.58K |
| Paradigm Biocapital Advisors LP | 900.00K | ▲ 900.00K |
| Geode Capital Management, LLC | 756.88K | ▲ 712.39K |
| Jupiter Topco LLC | 749.70K | ▲ 749.70K |
Held by 105 ETFs
Biggest fund positions in KARD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 29, 26 | Reinke Kristin Marie K | other | 48,368 |
| Sep 29, 26 | Reinke Kristin Marie K | other | 0 |
| Jun 17, 26 | PERCEPTIVE ADVISORS LLC | other | 20,706 |
| Jun 22, 26 | HRTG GPE, LLC | buy | 3,125,000 |
| Jun 17, 26 | HRTG GPE, LLC | other | 0 |
| Jun 17, 26 | HRTG GPE, LLC | other | 0 |
| Jun 17, 26 | HRTG GPE, LLC | other | 0 |
| Jun 17, 26 | HRTG GPE, LLC | other | 0 |
| Jun 17, 26 | HRTG GPE, LLC | other | 0 |
| Jun 22, 26 | BERNS PAUL L | buy | 1,250,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KARD coverage
Recent articles, reports, and earnings notes.
Want a deeper read on KARD?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates
businesswire.com · Nov 12
Kardigan to Participate in the Jefferies Global Healthcare Conference
businesswire.com · Nov 11
Kardigan, Inc. (KARD) Discusses Aortic Stenosis Progression Data and KATALYST-AV Baseline Findings Transcript
seekingalpha.com · Nov 7
Kardigan Extends Phase 2 Ataciguat Trial Assessment, Targets 2027 Results
marketbeat.com · Nov 7
Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis
businesswire.com · Nov 6
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Boston Scientific, eBay, Fervo Energy, Fortinet, Hilton Worldwide Holdings, Lennox International, Palantir Technologies, and More
247wallst.com · Oct 29
Kardigan Announces Appointment of Kristin Reinke to its Board of Directors
businesswire.com · Sep 30
Kardigan, Inc. (NASDAQ:KARD) Stock Has Consensus Price Target of $42.25 According to Analysts
defenseworld.net · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.